Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of 4.96 billion. The enterprise value is 2.42 billion.
Market Cap | 4.96B |
Enterprise Value | 2.42B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +18.37% |
Shares Change (QoQ) | +1.58% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 59.90M |
Valuation Ratios
The trailing PE ratio is 4.72.
PE Ratio | 4.72 |
Forward PE | n/a |
PS Ratio | 3.46 |
PB Ratio | 2.02 |
P/TBV Ratio | 2.02 |
P/FCF Ratio | 4.19 |
P/OCF Ratio | 4.18 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.14, with an EV/FCF ratio of 2.04.
EV / Earnings | 2.30 |
EV / Sales | 1.70 |
EV / EBITDA | 2.14 |
EV / EBIT | 2.15 |
EV / FCF | 2.04 |
Financial Position
The company has a current ratio of 15.09, with a Debt / Equity ratio of 0.03.
Current Ratio | 15.09 |
Quick Ratio | 15.08 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.06 |
Debt / FCF | 0.05 |
Interest Coverage | 224.24 |
Financial Efficiency
Return on equity (ROE) is 53.44% and return on invested capital (ROIC) is 34.83%.
Return on Equity (ROE) | 53.44% |
Return on Assets (ROA) | 32.86% |
Return on Invested Capital (ROIC) | 34.83% |
Return on Capital Employed (ROCE) | 44.76% |
Revenue Per Employee | 3.38M |
Profits Per Employee | 2.48M |
Employee Count | 335 |
Asset Turnover | 0.67 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 84.07 million in taxes.
Income Tax | 84.07M |
Effective Tax Rate | 7.40% |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 18.89 |
Average Volume (20 Days) | 235 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of 1.43 billion and earned 1.05 billion in profits. Earnings per share was 14.75.
Revenue | 1.43B |
Gross Profit | 1.44B |
Operating Income | 1.13B |
Pretax Income | 1.14B |
Net Income | 1.05B |
EBITDA | 1.13B |
EBIT | 1.13B |
Earnings Per Share (EPS) | 14.75 |
Balance Sheet
The company has 2.61 billion in cash and 62.49 million in debt, giving a net cash position of 2.55 billion.
Cash & Cash Equivalents | 2.61B |
Total Debt | 62.49M |
Net Cash | 2.55B |
Net Cash Per Share | n/a |
Equity (Book Value) | 2.46B |
Book Value Per Share | 34.91 |
Working Capital | 2.50B |
Cash Flow
In the last 12 months, operating cash flow was 1.19 billion and capital expenditures -2.25 million, giving a free cash flow of 1.19 billion.
Operating Cash Flow | 1.19B |
Capital Expenditures | -2.25M |
Free Cash Flow | 1.19B |
FCF Per Share | n/a |
Margins
Gross margin is 100.06%, with operating and profit margins of 78.88% and 73.34%.
Gross Margin | 100.06% |
Operating Margin | 78.88% |
Pretax Margin | 79.20% |
Profit Margin | 73.34% |
EBITDA Margin | 78.98% |
EBIT Margin | 78.88% |
FCF Margin | 82.64% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -18.37% |
Shareholder Yield | n/a |
Earnings Yield | 21.20% |
FCF Yield | 23.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 21.97 and a Piotroski F-Score of 6.
Altman Z-Score | 21.97 |
Piotroski F-Score | 6 |